Skip to main content
Premium Trial:

Request an Annual Quote

Eidogen-Sertanty To Use Informatics Platform in Collaboration with KAI Pharmaceuticals

NEW YORK, Oct. 18 (GenomeWeb News) - Eidogen-Sertanty said today that it has entered into an informatics-based collaboration with drug-discovery firm KAI Pharmaceuticals.

 

Under the terms of the collaboration, which will focus on the development of protein kinase C modulators, Eidogen-Sertanty will use its Target Informatics Platform and its EVE comparative visualization software to perform structural characterization and comparative binding site analysis for PKC regulatory domains.

 

KAI is developing modulators of PKCs for a variety of human diseases, and has a lead product in clinical development for acute cardiovascular diseases. The collaboration is expected to improve the pharmacophore-based design of modulators of PKC activity, Eidogen-Sertanty said.

The Scan

Interfering With Invasive Mussels

The Chicago Tribune reports that researchers are studying whether RNA interference- or CRISPR-based approaches can combat invasive freshwater mussels.

Participation Analysis

A new study finds that women tend to participate less at scientific meetings but that some changes can lead to increased involvement, the Guardian reports.

Right Whales' Decline

A research study plans to use genetic analysis to gain insight into population decline among North American right whales, according to CBC.

Science Papers Tie Rare Mutations to Short Stature, Immunodeficiency; Present Single-Cell Transcriptomics Map

In Science this week: pair of mutations in one gene uncovered in brothers with short stature and immunodeficiency, and more.